Back to discover
Drug

Plazomicin

In clinical development
Emerging researchLate-stage development

Also known as Zemdri.

RxNorm2049549ChEMBLCHEMBL1650559ATCJ01GB14UNIILYO9XZ250J
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1 Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intravenous Administration of Plazomicin in Subjects With End Stage Renal Disease (ESRD) Receiving Intermittent Hemodialysis (IHD)

Clinical trial2021-06-09Completed · ClinicalTrials.gov

New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.

Research2021-05-02Molecules (Basel, Switzerland)

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

Clinical trial2018-10-16Results posted · ClinicalTrials.gov

A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults

Clinical trial2018-08-23Results posted · ClinicalTrials.gov

A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis

Clinical trial2018-08-22Results posted · ClinicalTrials.gov

A Phase 1, Open Label, Randomized, 2-Period, 2-Treatment, Crossover Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects

Clinical trial2017-10-07Completed · ClinicalTrials.gov

A Phase 1, Open-Label Study to Assess the Metabolism, Excretion, and Mass Balance of [14C]-Plazomicin Following a Single IV Infusion in Healthy Adult Male Subjects

Clinical trial2017-07-10Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Plazomicin
Aliases & brands
Zemdri
RxNorm CUI
2049549
ChEMBL ID
CHEMBL1650559
ATC codes
J01GB14
UNII
LYO9XZ250J

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
6
registered trials across all phases
LATEST COMPLETION 2021
2
Late-stage (III+)
6
Completed
PHASE DISTRIBUTIONn = 6
Phase 13Phase 21Phase 32

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 1 Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intravenous Administration of Plazomicin in Subjects With End Stage Renal Disease (ESRD) Receiving Intermittent Hemodialysis (IHD)

CompletedPH ICipla USA Inc.n=62021

A Phase 1, Open Label, Randomized, 2-Period, 2-Treatment, Crossover Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects

CompletedPH IAchaogen, Inc.n=162017

A Phase 1, Open-Label Study to Assess the Metabolism, Excretion, and Mass Balance of [14C]-Plazomicin Following a Single IV Infusion in Healthy Adult Male Subjects

CompletedPH IAchaogen, Inc.n=62017

A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults

CompletedPH IIIAchaogen, Inc.n=6092016

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

CompletedPH IIIAchaogen, Inc.n=692016

A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis

CompletedPH IIAchaogen, Inc.n=1452012

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Drug Design1Drug Resistance, Multiple, Bacterial1
Journals, researchers & institutions
Top journals
  • Molecules (Basel, Switzerland)1
Leading researchers
  • Pregnolato M1
  • Taccani M1
  • Terreni M1
Leading institutions
free-text, unnormalised
  • University of Pavia1

Related drugs

7 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cefiderocol

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
Delafloxacin

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
Eravacycline

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
Meropenem

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
Pretomanid

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
Sisomicin

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
Vaborbactam

Studied across 2 of the same disease areas as Plazomicin in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials